Entinostat: a promising treatment option for patients with advanced breast cancer
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Entinostat is a synthetic benzamide derivative histone deacetylase (HDAC) inhibitor, which potently and selectively inhibits class I and IV HDAC enzymes. This action promotes histone hyperacetylation and transcriptional activation of specific genes, with subsequent inhibition of cell proliferation, terminal differentiation and apoptosis. This oral HDAC inhibitor has been evaluated in Phase I and II trials in patients with advanced malignancies, and is in general well tolerated. Entinostat does not currently have regulatory approval for clinical use; however promising preclinical and clinical data exist in hormone-resistant breast cancer. An ECOG-ACRIN Phase III registration study is ongoing in advanced breast cancer (E2112, NCT02115282) and aims to confirm the overall survival advantage observed with the combination of exemestane and entinostat/placebo in the Phase II setting (ENCORE301 trial). This article provides an overview of the chemistry, pharmacokinetics/pharmacodynamics and available clinical data for entinostat with a focus on advanced breast cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Entinostat, an oral HDAC inhibitor, induces protein lysine acetylation in preclinical models, which leads to downregulation of estrogen-independent growth factor signaling pathways and normalization of estrogen receptor levels.9,10”
Citations
Cites
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Deacetylase inhibition promotes the generation and function of regulatory T cells
Tao, R., de Zoeten, E. F., Özkaynak, E., Chen, C., Wang, L., Porrett, P. M., Li, B., Turka, L. A., Olson, E. N., Greene, M. I., et al. (2007) · Nature Medicine · doi:10.1038/nm1652 · Cited by 924
Saito, A., Yamashita, T., Mariko, Y., Nosaka, Y., Tsuchiya, K., Ando, T., Suzuki, T., Tsuruo, T., & Nakanishi, O. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4592 · Cited by 694
Juergens, R. A., Wrangle, J., Vendetti, F. P., Murphy, S. C., Zhao, M., Coleman, B., Sebree, R., Rodgers, K., Hooker, C. M., Franco, N., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0214 · Cited by 686
Self-citation
Research works printed but not linked: 1
- 10.1016/S1470-2045(14)71159-3 · DOI · Paper page
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
HDAC Inhibitors in Acute Myeloid Leukemia
San José-Enériz, E., Gimenez-Camino, N., Agirre, X., & Prosper, F. (2019) · Cancers · doi:10.3390/cancers11111794 · Cited by 222
“Entinostat (MS-275) is a synthetic benzamide derivative class I HDACi that potently and selectively leads to cell cycle arrest and hyperacetylation of histones H3 and H4 [167,193,194].”
BackgroundMolecular hybridization: a powerful tool for multitarget drug discovery
de Sena Murteira Pinheiro, P., Franco, L. S., Montagnoli, T. L., & Fraga, C. A. M. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2322990 · Cited by 204
The Chemical Biology of Reversible Lysine Post-translational Modifications
Wang, Z. A., & Cole, P. A. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.07.002 · Cited by 201
Hellmann, M. D., Jänne, P. A., Opyrchal, M., Hafez, N., Raez, L. E., Gabrilovich, D. I., Wang, F., Trepel, J. B., Lee, M.-J., Yuno, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3305 · Cited by 133
“HDAC inhibition has been demonstrated preclinically to improve immune competency through increased MHC presentation and tumor antigen expression and reduced number and function of immunosuppressive cells (15, 17 – 21), particularly myeloid-derived suppressor cells (MDSC; refs.21 ,22).”
Connolly, R. M., Zhao, F., Miller, K. D., Lee, M.-J., Piekarz, R. L., Smith, K. L., Brown-Glaberman, U. A., Winn, J. S., Faller, B. A., Onitilo, A. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00944 · Cited by 125
“independent growth factor signaling pathways and normalization of estrogen receptor levels.(9,10) Entinostat has also overcome endocrine therapy resistance in letrozoleresistant mouse models.”
BackgroundSelf-citationTherapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment
Sun, Y., Hong, J. H., Ning, Z., Pan, D., Fu, X., Lu, X., & Tan, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.932914 · Cited by 94
“patients, but its efficacy as a single agent therapy remains limited (Connolly et al., 2017).”
BackgroundEpigenetic regulation in cancer therapy: From mechanisms to clinical advances
Tao, L., Zhou, Y., Luo, Y., Qiu, J., Xiao, Y., Zou, J., Zhang, Y., Liu, X., Yang, X., Gou, K., et al. (2024) · MedComm – Oncology · doi:10.1002/mog2.59 · Cited by 111
Mondal, P., Natesh, J., Penta, D., & Meeran, S. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.006 · Cited by 96
Hicks, K. C., Chariou, P. L., Ozawa, Y., Minnar, C. M., Knudson, K. M., Meyer, T. J., Bian, J., Cam, M., Schlom, J., & Gameiro, S. R. (2021) · Nature Communications · doi:10.1038/s41467-021-25393-x · Cited by 83
Small molecule HDAC inhibitors: Promising agents for breast cancer treatment
Huang, M., Zhang, J., Yan, C., Li, X., Zhang, J., & Ling, R. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103184 · Cited by 77
The role of histone deacetylase inhibitors in metastatic breast cancer
Zucchetti, B. M., Shimada, A. K., Katz, A., & Curigliano, G. (2018) · The Breast · doi:10.1016/j.breast.2018.12.001 · Cited by 74
Maiti, A., Qi, Q., Peng, X., Yan, L., Takabe, K., & Hait, N. C. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4796 · Cited by 80
“A specific inhibitor of these HDACs, entinostat, has undergone clinical phase II trials for the treatment of solid cancers, including advanced breast cancer and is well tolerated (94,95).”
BackgroundXu, B., Zhang, Q., Hu, X., Li, Q., Sun, T., Li, W., Ouyang, Q., Wang, J., Tong, Z., Yan, M., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.001 · Cited by 74
Banik, D., Noonepalle, S. K. R., Hadley, M. M., Palmer, E., Gracia-Hernandez, M., Delgado, C. Z., Manhas, N., Simonyan, H., Young, C. N., Popratiloff, A. S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3738 · Cited by 74
“31), class I inhibitor entinostat, both utilized in clinical studies for its anticancer properties (32), and a second HDAC6 inhibitor SS-2-08 (26) via a triplex assay Apotox.”
BackgroundHistone Deacetylases and Their Inhibitors in Cancer Epigenetics
Hassell, K. N. (2019) · Diseases · doi:10.3390/diseases7040057 · Cited by 77
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
Ružić, D., Djoković, N., Srdić‐Rajić, T., Echeverría, C., Nikolic, K. M., & Santibanez, J. F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010209 · Cited by 70
Zhuang, J., Huo, Q., Yang, F., & Xie, N. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.603552 · Cited by 74
Ong, M. S., Cai, W., Yuan, Y., Leong, H. C., Tan, T. Z., Mohammad, A., You, M., Arfuso, F., Goh, B. C., Warrier, S. R., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13958 · Cited by 63
“In addition, other potential therapeutic agents also include COX-2 inhibitors (celecoxib in ovarian cancer trials) and histone deacetylase inhibitors (entinostat in breast cancer) (Zagouri et al., 2012; Connolly et al., 2017).”
BackgroundLian, B., Chen, X., & Shen, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1164514 · Cited by 75
Wang, H., Milberg, O., Bartelink, I. H., Vicini, P., Wang, B., Narwal, R., Roskos, L., Santa-Maria, C. A., & Popel, A. S. (2019) · Royal Society Open Science · doi:10.1098/rsos.190366 · Cited by 60
HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
Maccallini, C., Ammazzalorso, A., Filippis, B. D., Fantacuzzi, M., Giampietro, L., & Amoroso, R. (2022) · Pharmaceuticals · doi:10.3390/ph15060667 · Cited by 59
“For example, Entinostat and Tucidinostat are benzamide-based Class-I selective HDAC inhibitors (Figure 3) currently under clinical evaluation in both the US and Europe for the treatment of both cancer and nononcological diseases [13,14].”
Sauer, S. J., Reed, D. R., Ihnat, M. A., Hurst, R. E., Warshawsky, D., & Barkan, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659963 · Cited by 63
Kiweler, N., Gül, D., Wirth, M., Mahendrarajah, N., Schneider, G., Stauber, R. H., Brenner, W., Butter, F., & Krämer, O. H. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03118-4 · Cited by 59
Minnar, C. M., Chariou, P. L., Horn, L. A., Hicks, K. C., Palena, C., Schlom, J., & Gameiro, S. R. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004561 · Cited by 62
Pulya, S., Patel, T. K., Paul, M., Adhikari, N., Banerjee, S., Routholla, G., Biswas, S., Jha, T., & Ghosh, B. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114470 · Cited by 56
Wang, H., Sové, R. J., Jafarnejad, M., Rahmeh, S., Jaffee, E. M., Stearns, V., Torres, E. T. R., Connolly, R. M., & Popel, A. S. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00141 · Cited by 51
Self-citationModulation of Antitumor Immunity with Histone Deacetylase Inhibitors
McCaw, T. R., Randall, T. D., Forero, A., & Buchsbaum, D. J. (2017) · Immunotherapy · doi:10.2217/imt-2017-0134 · Cited by 49
Chianese, A., Santella, B., Ambrosino, A., Stelitano, D., Rinaldi, L., Galdiero, M., Zannella, C., & Franci, G. (2021) · Cancers · doi:10.3390/cancers13112761 · Cited by 50
“To date, it has not yet received approval for clinical use, but the US FDA allowed its combinatorial treatment with exemestane for the management of advanced breast cancer [229].”
BackgroundProminent Role of Histone Modifications in the Regulation of Tumor Metastasis
Markouli, M., Strepkos, D., Basdra, E. K., Papavassiliou, A. G., & Piperi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052778 · Cited by 52
“HDACi prevent breast tumor progression via transcriptional inhibition of EMT-related genes, modulation of human epidermal growth factor receptor 2 (HER2) expression or induction of estrogen receptor (ER) in hormone receptor-negative tumors, as well as by increasing the sensitivity of hormonal therapy in ER positive tu…”
BackgroundHicks, K. C., Knudson, K. M., Lee, K. L., Hamilton, D. H., Hodge, J. W., Figg, W. D., Ordentlich, P., Jones, F. R., Rabizadeh, S., Soon-Shiong, P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0727 · Cited by 44
“This is concordant with reports of transient, non–dose-limiting leukopenia observed in some patients treated with entinostat (32, 33).”
MethodResultUnconventional protein post-translational modifications: the helmsmen in breast cancer
Liu, J., Wang, Q., Kang, Y., Xu, S., & Pang, D. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00756-z · Cited by 45
“NCT02115282 [253, 240] Entinostat in Patients With Recurrent Advanced Hormone Receptor-Positive Breast Cancer III Recurrent Breast Carcinoma Drug: Entinostat Drug: Exemestane Drug: Goserelin Acetate Active, not recruiting”
BackgroundSchiaffino, L., Bonafede, R., Scambi, I., Parrella, E., Pizzi, M., & Mariotti, R. (2018) · Scientific Reports · doi:10.1038/s41598-018-30659-4 · Cited by 42
Pramanik, S. D., Halder, A. K., Mukherjee, U., Kumar, D., Dey, Y. N., & Mogana, R. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.948217 · Cited by 47
“HDACi have been tested in all breast cancer subtypes because preclinical research shows that this class of drug can target breast cancer in a variety of ways, including relief of transcriptional repression with an impact on the epithelial-mesenchymal transition (EMT), reactivation of silenced oestrogen receptor (ER) i…”
BackgroundNetwork-Based Analysis of Fatal Comorbidities of COVID-19 and Potential Therapeutics
Chakrabarty, B., Das, D., Bulusu, G., & Roy, A. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3075299 · Cited by 38
“Entinostat [88] is under investigation for the”
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment
Gianni, C., Palleschi, M., Schepisi, G., Casadei, C., Bleve, S., Merloni, F., Sirico, M., Sarti, S., Cecconetto, L., Menna, G. D., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.882896 · Cited by 42
Ghorbaninejad, M., Khademi-Shirvan, M., Hosseini, S., & Eslaminejad, M. B. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01966-3 · Cited by 35
Recent advancement of HDAC inhibitors against breast cancer
Mehmood, S. A., Sahu, K. K., Sengupta, S., Partap, S., Karpoormath, R. V., Kumar, B., & Kumar, D. (2023) · Medical Oncology · doi:10.1007/s12032-023-02058-x · Cited by 37
Wang, R., Dong, X., Zhang, X., Liao, J., Cui, W., & Li, W. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.103877 · Cited by 40
“…II NCT04296942[201] BN-Brachyury+Entinostat+Adotrastuzumab Emtansine+M7824 I NCT02623751[202] KHK2375+Exemestane I NCT02115282[203, 204] Entinostat III NCT02833155[205] Entinostat+Exemestane I NCT02632071[206] ACY-1215+Nab-paclitaxel I Lymphoma NCT01742988[207, 208] CUDC-907 I…”
Neerathilingam, N., Reddy, M. B., & Anandhan, R. (2021) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.1c01792 · Cited by 31
Solta, A., Boettiger, K., Kovács, I., Lang, C., Megyesfalvi, Z., Ferk, F., Mišík, M., Hoetzenecker, K., Aigner, C., Kowol, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1795 · Cited by 22
“Entinostat (MS-275) is currently being tested in clinical trials for the treatment of various malignancies such as breast, lung, bladder, colorectal, and renal cancers (17).”
Histone deacetylase inhibitors for leukemia treatment: current status and future directions
Hosseini, M., Sanaat, Z., Akbarzadeh, M. A., Vaez-Gharamaleki, Y., & Akbarzadeh, M. (2024) · European journal of medical research · doi:10.1186/s40001-024-02108-8 · Cited by 30
“Entinostat, (MS-275, SNDX-275), is a synthetic benza-mide derivative that selectively inhibits class I HDAC [82].”
BackgroundPal, D., Raj, K., Nandi, S. S., Sinha, S., Mishra, A., Mondal, A., Lagoa, R., Burcher, J. T., & Bishayee, A. (2023) · Cancers · doi:10.3390/cancers15102808 · Cited by 30
Merino, V. F., Cho, S., Nguyen, N., Sadik, H., Narayan, A., Talbot, C. C., Cope, L., Zhou, X., Zhang, Z., Győrffy, B., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1068-x · Cited by 28
Ma, S., Liu, T., Xu, L., Wang, Y., Zhou, J., Huang, T., Li, P., Liu, H., Zhang, Y.-T. Y., Zhou, X., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28805 · Cited by 28
Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors
Liu, Z., Gao, Y., & Li, X. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1552139 · Cited by 29
“receptor (ER)-positive breast cancer, based on results from the Phase II trial (ENCORE 301 trial) [65].”
BackgroundUnlocking the epigenetic code: new insights into triple-negative breast cancer
Mahendran, G., Shangaradas, A. D., Romero-Moreno, R., Dona, N. W., Sarasija, S. H. G. S., Perera, S., & Silva, G. N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1499950 · Cited by 29
Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells
Maietta, I., Martínez-Pérez, A., Álvarez, R., de Lera, Á. R., González‐Fernández, Á., & Simón‐Vázquez, R. (2022) · Pharmaceuticals · doi:10.3390/ph15070824 · Cited by 27
The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations
Esfahani, M. A., Servatian, N., Al-Athari, A. J. H., Khafaja, E. S. M., Seraji, H. R., & Samarkhazan, H. S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01783-z · Cited by 24
“However, enti-nostat (MS-275, SNDX-275) is a synthetic derivative of the benzamide class and inhibits only HDAC1 [109].”
Cavallo, F., Troglio, F., Fagà, G., Fancelli, D., Shyti, R., Trattaro, S., Zanella, M., D’Agostino, G. A., Hughes, J. M., Cera, M. R., et al. (2020) · Molecular Autism · doi:10.1186/s13229-020-00387-6 · Cited by 25
Kurmasheva, R. T., Bandyopadhyay, A. M., Favours, E., Pozo, V. D., Ghilu, S., Phelps, D. A., Erickson, S. W., Peer, C. J., Figg, W. D., Smith, M. A., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27820 · Cited by 23
E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors
Decourtye, L., Bougen-Zhukov, N. M., Godwin, T. D., Brew, T. P., Schulpen, E., Black, M. A., & Guilford, P. (2021) · Cancers · doi:10.3390/cancers14010175 · Cited by 23
“The differential inhibition between wild-type and CDH1-null cells was frequently statistically significant at sub-micromolar concentrations and consistent with the effective concentrations observed in numerous cancer cell lines [17,48,49].”
BackgroundGorshkov, K., Sima, N., Sun, W., Lu, B., Huang, W., Travers, J., Klumpp-Thomas, C. A., Michael, S., Xu, T., Huang, R., et al. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.11.016 · Cited by 23
“98 μM; SI N100) and entinostat [30,31] (IC50 = 7.”
Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy
Wolfson, B., Franks, S. E., & Hodge, J. W. (2021) · Vaccines · doi:10.3390/vaccines9050509 · Cited by 22
“Entinostat, a selective inhibitor of class I and IV HDAC enzymes resulting in a block of cell proliferation and differentiation, and ultimately leading to apoptosis [65], has shown promising results in phase I and II trials (reviewed here; [66]).”
BackgroundJun, an Oncological Foe or Friend?
Jafri, Z., Li, Y., Zhang, J., O’Meara, C. H., & Khachigian, L. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020555 · Cited by 25
Wahi, A., Jain, P., Sinhari, A., & Jadhav, H. R. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02674-4 · Cited by 25
SIRT6 promotes metastasis and relapse in HER2-positive breast cancer
Andreani, C., Bartolacci, C., Persico, G., Casciaro, F., Amatori, S., Fanelli, M., Giorgio, M., Galiè, M., Tomassoni, D., Wang, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-49199-7 · Cited by 23
“…genes in SIRT6-OE tumors significantly overlap with the proteomic signature upregulated in cells treated with entinostat, a histone deacetylase (HDAC) drug inhibitor used as breast cancer therapy 68 , confirming that this gene set is indeed regulated by histone acetylation in breast cancer (Fig.”
Clinical impact of epithelial–mesenchymal transition for cancer therapy
Mukerjee, N., Nag, S., Bhattacharya, B., Alexiou, A. T., Mirgh, D., Mukherjee, D., Adhikari, M. D., Anand, K., Muthusamy, R., Gorai, S., et al. (2024) · Clinical and Translational Discovery · doi:10.1002/ctd2.260 · Cited by 30
Super-Enhancers and Their Parts: From Prediction Efforts to Pathognomonic Status
Vasileva, A. V., Gladkova, M. G., Ashniev, G. A., Osintseva, E. D., Орлов, А. В., Kravchuk, E. V., Boldyreva, A., Burenin, A. G., Nikitin, P. I., & Orlova, N. N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063103 · Cited by 24
Bello, E. D., Sian, V., Bontempi, G., Zwergel, C., Fioravanti, R., Noce, B., Castiello, C., Tomassi, S., Corinti, D., Passeri, D., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115022 · Cited by 20
Evolution of Slow-Binding Inhibitors Targeting Histone Deacetylase Isoforms
Mukherjee, A., Zamani, F., & Suzuki, T. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01160 · Cited by 23
Terri, M., Sandoval, P., Bontempi, G., Montaldo, C., Tomero‐Sanz, H., de Turris, V., Trionfetti, F., Pascual‐Antón, L., Clares, I., Battistelli, C., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02930-8 · Cited by 21
Bai, X., Jiang, H., Han, G., & He, Q. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10425 · Cited by 19
Kumar, K. K., Aburawi, E. H., Ljubisavljević, M., Leow, M. K., Xu, F., Ansari, S. A., & Emerald, B. S. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01692-0 · Cited by 24
“HDAC-i, MS275 inhibits HDAC-1, 2, and 3 and reduces the activity of the pro-apoptotic protein caspase-3 [196].”
BackgroundHistone deacetylase inhibitors as antidiabetic agents: Advances and opportunities
Sonthalia, M., Roy, B. S., Chandrawanshi, D., Ganesh, G. V., Jayasuriya, R., Mohandas, S., Rajagopal, S., & Ramkumar, K. M. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175328 · Cited by 18
Coschi, C. H., & Juergens, R. A. (2023) · Current Oncology · doi:10.3390/curroncol31010001 · Cited by 26
“Entinostat, a histone deacetylase (HDAC) inhibitor, has been shown to negatively affect MDSCs [123,124].”
BackgroundBele, S. D., Girada, S. B., Ray, A., Gupta, A., Oruganti, S., Babu, P. P., Rayalla, R. S., Kalivendi, S. V., Ibrahim, A., Puri, V., et al. (2020) · eLife · doi:10.7554/elife.52212 · Cited by 18
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
Vaca, H. R., Celentano, A. M., Toscanini, M. A., Heimburg, T., Ghazy, E., Zeyen, P., Hauser, A., Oliveira, G., Elissondo, M. C., Jung, M., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009226 · Cited by 21
“Since this compound is undergoing phase III clinical trials to treat various cancers and has been granted breakthrough therapy status by the FDA [60], entinostat deserves further consideration as a cestocidal drug.”
BackgroundRaouf, Y. S., Sedighi, A., Geletu, M., Frere, G. A., Allan, R. G., Nawar, N., de Araujo, E. D., & Gunning, P. T. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01236 · Cited by 17
Jo, D., Kaczmarek, S., Khan, A. U. H., Pervin, J., Clark, D. M., Gadde, S., Wang, L., McComb, S., Visram, A., & Lee, S. H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1533044 · Cited by 18
Iwata, H., Nakamura, R., Masuda, N., Yamashita, T., Yamamoto, Y., Kobayashi, K., Tsurutani, J., Iwasa, T., Yonemori, K., Tamura, K., et al. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac166 · Cited by 16
Lamoine, S., Cuménal, M., Barrière, D. A., Pereira, V., Fereyrolles, M., Prival, L., Barbier, J., Boudieu, L., Brasset, É., Bertin, B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010098 · Cited by 20
“4 μM after MS-275 administration in humans [38], whereas therapeutically achievable concentrations of oxaliplatin have been reported to be around 5–10 μM [39].”
BackgroundLu, S., Liang, Y. Q., Li, L., Liao, S., Zou, Y., Yang, C., & Ouyang, D. (2023) · BMC Genomics · doi:10.1186/s12864-023-09899-w · Cited by 15
Shoyaib, A. A., Alamri, F. F., Syeara, N., Jayaraman, S., Karamyan, S. T., Arumugam, T. V., & Karamyan, V. T. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-021-08647-1 · Cited by 16
Costanzo, G., Buccheri, R., Cosentino, G., Reale, C., Zuccalà, S., Marrazzo, A., Amata, E., Rescifina, A., & Pasquinucci, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117998 · Cited by 15
AbdAllah, A. (2026) · RSC Advances · doi:10.1039/d5ra09034b · Cited by 20
“85 While mocetinostat 14 received from FDA an orphan drug designation for DLBCL. 86,87 Benzamides have common phar-macophoric features similar to those of hydroxamic acid derivatives, including a Zn binding group, a hydrophobic spacer, a polar connection unit, and a CAP group.”
Bioorthogonal Drug Release from Nanometric Micelles in Living Cells
Madegard, L., Girard, M., Riss‐Yaw, B., Porte, K., Audisio, D., Papot, S., & Taran, F. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202301359 · Cited by 14
HDAC inhibitor enhances ferroptosis susceptibility of AML cells by stimulating iron metabolism
Bian, R., Shang, Y., Xu, N., Liu, B., Ma, Y., Li, H., Chen, J., & Yao, Q. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111583 · Cited by 16
A new strategy for overcoming drug resistance in liver cancer: Epigenetic regulation
Su, X., Li, Y., Ren, Y., Cao, M., Yang, G., Luo, J., Hu, Z., Deng, H., Deng, M., Liu, B., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116902 · Cited by 15
Navarro, P., Grazioso, T. P., Barquín, A., Barba, M., Yagüe, M., Millán, C., López, I., Sevillano, E., Quiralte, M., Fernández, P., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03437-0 · Cited by 16
Overcoming immune suppression with epigenetic modification in ovarian cancer
McCaw, T. R., Randall, T. D., & Arend, R. C. (2018) · Translational research · doi:10.1016/j.trsl.2018.06.003 · Cited by 14
Buonvicino, D., Ranieri, G., & Chiarugi, A. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.04.002 · Cited by 12
Rational Design and Development of HDAC Inhibitors for Breast Cancer Treatment
Mody, D., Bouckaert, J. M. J., Savvides, S. N., & Gupta, V. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666210917143953 · Cited by 13
“romidepsin (136), tucidinostat (137), and entinostat (138).”
Targeting the Epigenome as a Novel Therapeutic Approach for Breast Cancer
Oh, S., Ko, J. Y., Oh, C., & Yoo, K. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_14 · Cited by 12
Development of 2-Morpholino-N-hydroxybenzamides as anti-proliferative PC-PLC inhibitors
Rees, S. W. P., Leung, E. Y., Reynisson, J., Barker, D. L. A., & Pilkington, L. I. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105152 · Cited by 11
Immune Checkpoint Inhibitors and Combinations with Other Agents in Cholangiocarcinoma
Skouteris, N., Papageorgiou, G., Fioretzaki, R., Schizas, D., Kykalos, S., Tolia, M., & Charalampakis, N. (2023) · Immunotherapy · doi:10.2217/imt-2022-0225 · Cited by 12
Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions
Devaraji, M., & Cheriyan, B. V. (2025) · Journal of the Egyptian National Cancer Institute · doi:10.1186/s43046-025-00319-6 · Cited by 21
“Similarly, metformin and IDO inhibitors are under investigation for their ability to reprogram tumor metabolism and overcome T-cell exhaustion [237].”
Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies
Giercuszkiewicz-Haśnik, K., MORAK-MŁODAWSKA, B. I., & Jeleń, M. (2026) · Molecules · doi:10.3390/molecules31071195 · Cited by 15
Berckmans, Y., Hoffert, Y., Vankerckhoven, A., Dreesen, E., & Coosemans, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071792 · Cited by 14
“Side effects can occur and include fatigue, nausea, vomiting, diarrhea, hematologic toxicity (anemia, neutropenia, thrombocytopenia), dyspnea, peripheral edema, and decreased weight [51].”
BackgroundPeat, T. J., Gaikwad, S. M., Dubois, W., Gyabaah-Kessie, N., Zhang, S., Gorjifard, S., Phyo, Z. H., Andres, M., Hughitt, V. K., Simpson, R. J., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216284 · Cited by 12
Beyond the Usual Suspects: Examining the Role of Understudied Histone Variants in Breast Cancer
Dhahri, H., Saintilnord, W. N., Chandler, D., & Fondufe‐Mittendorf, Y. N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126788 · Cited by 9
Trionfetti, F., Alonzi, T., Bontempi, G., Terri, M., Battistelli, C., Montaldo, C., Repele, F., Rotili, D., Valente, S., Zwergel, C., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1257683 · Cited by 10
Giri, P. M., Kumar, A., Salu, P., Sathish, V., Reindl, K. M., Mallik, S., & Layek, B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116743 · Cited by 13
“On the other hand, ENT-mediated histone hyperacetylation promotes transcriptional activation of cancer-related genes, inhibiting tumor cell proliferation and differentiation while inducing apoptosis [35].”
BackgroundFlores, B., Uppalapati, C. K., Pascual, A. S., Vong, A., Baatz, M., Harrison, A. M., Leyva, K. J., & Hull, E. E. (2023) · Biomolecules · doi:10.3390/biom13111588 · Cited by 8
Govers, A. M. A. P., Wiggers, C. R. M., van Boxtel, R., Mokrý, M., Nieuwenhuis, E. E. S., Creyghton, M. P., Bartels, M., & Coffer, P. J. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000270 · Cited by 10
Mustafa, N., Mustafa, M. T., Abushanab, A. K., Alakhras, H. M., Abed, A. S., Bani-Said, S. A., Othman, L. S., & Shdaifat, A. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07737-z · Cited by 9
“In addition, the safety profile of this combination therapy raises concerns due to the possibility of increased adverse events (AEs) [15].”
Booth, S. W., Eyre, T. A., Whittaker, J. A., Campo, L., Wang, L. M., Soilleux, E. J., Royston, D. J., Rees, G., Kesavan, M., Hildyard, C., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08595-w · Cited by 8
“In contrast to the experimental HDAC inhibitor entinostat, which is orally bioavailable but inhibits both class 1 and class 4 HDACs, the half-life of CXD101 is considerably shorter (5–12 h) compared to 33–150 h) [16], reducing potential issues with accumulation and prolonged washout periods.”
Karimi, A. R., Nikravesh, G., Bayat, F., Khodadadi, A., & Tarighatjoo, M. (2019) · ChemistrySelect · doi:10.1002/slct.201902045 · Cited by 7
Nanoparticles decorated with granulocyte-colony stimulating factor for targeting myeloid cells
Margulis, K., Honkala, A. T., Kalashnikova, I. V., Noll, S. E., Hill, M. L., Zare, R. N., & Smith, B. R. (2020) · Nanoscale · doi:10.1039/c9nr06494j · Cited by 7
Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy
Poppe, L. K., Roller, N., Medina-Enríquez, M. M., Lassoued, W., Burnett, D., Lothstein, K. E., Khelifa, A. S., Miyamoto, M., Gulley, J. L., Jochéms, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011074 · Cited by 8
“38 Previous preclinical studies with Entinostat have shown strong synergy with sequential NHS-IL12 administration.”
Metadata
- Authors
- Connolly, R. M., Rudek, M. A., & Piekarz, R.
- Affiliations
- Sidney Kimmel Comprehensive Cancer Center,Johns Hopkins School of Medicine, Baltimore, MD, USA
- Johns Hopkins University (US)
- National Institutes of Health (US)
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2017-03-09
- Volume
- 13
- Issue
- 13
- Pages
- 1137-1148
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- PMC
- PMC5618943
- OpenAlex
- W2591958823
- Cited by
- 148
- References
- 66
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 22 · 2023: 22 · 2022: 16 · 2021: 19 · 2020: 15 · 2019: 14 · 2018: 7 · 2017: 3
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Future Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Celgene
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- entinostat, histone deacetylase inhibitors, advanced breast cancer, hormone-resistant breast cancer, histone hyperacetylation, benzamide derivatives, pharmacokinetics, pharmacodynamics, anticancer drug development
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Female, Humans, Neoplasm Staging, Pyridines, Apoptosis, Epigenesis, Genetic, Cell Line, Tumor, Cell Proliferation, Histone Deacetylase Inhibitors, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.